Orthocell Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Paul Anderson

Chief Executive Officer (CEO)

AU$651.0k

Compensación total

Porcentaje del salario del CEO	64.5%
Permanencia del CEO	18.1yrs
Participación del CEO	1.8%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Recent updates

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Anderson en comparación con los beneficios de Orthocell?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$7m
Jun 30 2023	AU$651k	AU$420k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$531k	AU$380k	-AU$9m
Mar 31 2022	n/a	n/a	-AU$9m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$9m
Jun 30 2021	AU$1m	AU$375k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$9m
Dec 31 2020	n/a	n/a	-AU$8m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$578k	AU$370k	-AU$6m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$7m
Sep 30 2019	n/a	n/a	-AU$6m
Jun 30 2019	AU$582k	AU$365k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$6m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$6m
Jun 30 2018	AU$597k	AU$365k	-AU$6m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$2m
Sep 30 2017	n/a	n/a	-AU$3m
Jun 30 2017	AU$533k	AU$350k	-AU$4m

Compensación vs. Mercado: La compensación total de Paul($USD419.85K) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD289.12K).

Compensación vs. Ingresos: La compensación de Paul ha aumentado mientras la empresa no es rentable.

CEO

Paul Anderson (57 yo)

18.1yrs

Permanencia

AU$650,974

Compensación

Mr. Paul Frederick Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson ha...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Anderson	CEO, MD & Executive Director	no data	AU$650.97k	1.81% A$ 1.4m
Nicole Telford	Chief Financial Officer	no data	sin datos	1.49% A$ 1.2m
Alex McHenry	Chief Operating Officer	5.3yrs	sin datos	sin datos
Ming Hao Zheng	Chief Scientific Officer and Member of Medical & Scientific Advisory Board	no data	sin datos	1.63% A$ 1.3m
Tony Macintyre	Chief Technical Operations Officer	1.3yrs	sin datos	sin datos
Peter Webse	Company Secretary	1.1yrs	sin datos	sin datos

1.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de OCC no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Anderson	CEO, MD & Executive Director	18.1yrs	AU$650.97k	1.81% A$ 1.4m
Ming Hao Zheng	Chief Scientific Officer and Member of Medical & Scientific Advisory Board	no data	sin datos	1.63% A$ 1.3m
Fiona Wood	Independent Non-Executive Director	less than a year	AU$31.80k	0.0077% A$ 6.1k
Samuel Asculai	Chairman of Medical & Scientific Advisory Board	no data	sin datos	sin datos
Ray Crowe	Member of Medical & Scientific Advisory Board	no data	sin datos	sin datos
Gregory Janes	Member of Medical & Scientific Advisory Board	no data	sin datos	sin datos
David Wood	Member of Medical & Scientific Advisory Board	no data	sin datos	sin datos
Alan Wang	Member of Medical & Scientific Advisory Board	no data	sin datos	sin datos
John Van Der Wielen	Independent Non-Executive Chairman	less than a year	AU$658.12k	0.16% A$ 121.9k
Rocky Tuan	Member of Medical & Scientific Advisory Board	8.1yrs	sin datos	sin datos
Massimo Simion	Member of Medical & Scientific Advisory Board	6.1yrs	sin datos	sin datos
Giuseppe Luongo	Member of Medical & Scientific Advisory Board	6.1yrs	sin datos	sin datos

6.1yrs

Permanencia media

Junta con experiencia: La junta directiva de OCC se considera experimentada (6.1 años de antigüedad promedio).

Orthocell Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media